Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection.
As more pharmacogenomic insights into diseases and their treatments and toxicities are published each year, the challenge arises to incorporate such insights into clinical practice and drug development. For instance, recent genomic discoveries related to hepatitis C offer a challenge to clinicians, researchers,and health administrators to translate this information into knowledge in order to develop safer and more effective therapeutic strategies for all patients.
Clark
P J
PJ
Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA. paul.clark@duke.edu
Thompson
A J V
AJ
McHutchison
J G
JG
D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D055808:Drug Discovery; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D057170:Translational Research, Biomedical; D000095022:Interferon Lambda
D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda